08HH.F SHANG.FOS.PHARM.GR.H YC 1
- Market cap
- EUR 5.04B
- P/E
- 11.1x
- P/B
- 0.78x
- ROE
- 7.1%
- Dividend yield
- 2.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 08HH.F undervalued?
Graham number08HH.F trades 38.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SHANG.FOS.PHARM.GR.H YC 1 fundamental analysis
No fundamental analysis for SHANG.FOS.PHARM.GR.H YC 1 yet.
SHANG.FOS.PHARM.GR.H YC 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SHANG.FOS.PHARM.GR.H YC 1
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabo…
Full company profileSHANG.FOS.PHARM.GR.H YC 1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SHANG.FOS.PHARM.GR.H YC 1 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 39.0B | 44.0B | 41.4B | 41.1B | 41.7B | 40.6B |
| Gross Profit | 18.8B | 20.8B | 19.8B | 19.7B | 20.9B | 20.2B |
| Operating Income | 2.71B | 3.64B | 1.56B | 3.20B | 3.15B | 3.11B |
| EBITDA | - | 7.87B | 7.55B | 8.60B | 9.89B | 6.40B |
| Net Income | 4.73B | 3.73B | 2.39B | 2.77B | 3.37B | 3.56B |
| EPS | 1.85 | 1.40 | 0.89 | 1.04 | 1.26 | 1.33 |
| Balance Sheet | ||||||
| Total Assets | 93.3B | 107B | 113B | 117B | 120B | 127B |
| Total Liabilities | 44.9B | 53.1B | 56.9B | 57.5B | 58.2B | 60.7B |
| Shareholders' Equity | 39.2B | 44.6B | 45.7B | 47.3B | 48.7B | 50.3B |
| Cash & Short-term Investments | 10.3B | 16.2B | 13.7B | 13.5B | 13.1B | 13.3B |
| Cash Flow | ||||||
| Operating Cash Flow | 3.94B | 4.22B | 3.41B | 4.48B | 5.21B | - |
| Capital Expenditure | 4.97B | 5.89B | 5.34B | 4.41B | 4.45B | 5.69B |
| Free Cash Flow | -1.03B | -1.67B | -1.92B | 66.8M | 765M | -1.12B |
| Ratios | ||||||
| ROE | 12.1% | 8.4% | 5.2% | 5.9% | 6.9% | 7.1% |
| ROA | 5.1% | 3.5% | 2.1% | 2.4% | 2.8% | 2.8% |
| Net Profit Margin | 12.1% | 8.5% | 5.8% | 6.7% | 8.1% | 8.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SHANG.FOS.PHARM.GR.H YC 1 dividends
- Dividend yield
- 2.61%
- Forward dividend
- 0.05 EUR
- Payout ratio
- 57.7%
- Ex-dividend date
- Jul 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.94B | 0.73 | 57.7% |
| 2024 | CNY 2.06B | 0.77 | 74.4% |
| 2023 | CNY 2.46B | 0.92 | 102.9% |
| 2022 | CNY 2.37B | 0.89 | 63.6% |
| 2021 | CNY 1.91B | 0.75 | 40.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns SHANG.FOS.PHARM.GR.H YC 1
- Insiders 14.85%
- Institutions 25.13%
- Public & others 60.03%
- Shares outstanding 552M
- Free float 1.65B
SHANG.FOS.PHARM.GR.H YC 1 company profile
- Company name
- SHANG.FOS.PHARM.GR.H YC 1
- Ticker
- 08HH.F
- ISIN
- CNE100001M79
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 40,603
- Fiscal year end
- December
- Address
- Building A, Shanghai, China, 200233
- Phone
- 86 21 3398 7000
- Website
- fosunpharma.com
About SHANG.FOS.PHARM.GR.H YC 1
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
SHANG.FOS.PHARM.GR.H YC 1 management
10- Ms. Xiaohui GuanExecutive Co-Chairman · born 1971
- Mr. Yuqing ChenExecutive Chairman · born 1975
- Dr. Yi LiuCEO, Chair of Fosun MedTech, Co-Chair of Innovative Medicines Division & Exec Director · born 1975
- Mr. Deyong WenExecutive Vice Chairman · born 1971
- Ms. Rongli FengExecutive President & Chief Human Resources Officer · born 1975
- Ms. Jing LiCo-President and CEO of Mature Products and Manufacturing Business Unit · born 1972
- Dr. Xingli Wang M.D., Ph.D.Co-President & CEO of the Innovative Drugs Business Unit · born 1962
- Mr. Xiang Li DPHILSVP, Co-President & CSO of the Innovative Drugs Business Unit · born 1966
- Ms. Jia YanChief Accountant, Co-CFO & Assistant to the President and Employee Director · born 1982
- Ms. Yue ZhuVP & GM of Legal Department · born 1977